Antenatal steroid use and neonatal outcome

United States 2007

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Antenatal steroid use has been associated with reduction in the risk of neonatal mortality in meta-analyses of clinical trials. In 2007, a revised US birth certificate offered information on antenatal steroid use in 22 states. The aim of this study was to review the association between antenatal steroid use and neonatal mortality by gestational age categories for preterm infants (<37 weeks) for the United States for the year 2007. Study Design: Data were obtained from the United States Linked Infant Birth and Death Certificate Public Use Period file for the year 2007. Associations between antenatal steroid use and neonatal death were determined by logistic regression adjusting for potentially confounding variables. Result: There were 245 453 preterm births and 4220 neonatal deaths available for analysis with complete data on antenatal steroid use. The highest prevalence for antenatal steroid use among neonatal intensive care unit admissions (NICU) was 22% in the 26 to 28 week gestational age category, whereas the lowest prevalence was in the 34-to 36-week group at 7%. Following adjustment for potentially confounding variables by logistic regression, the adjusted odds ratios (95% confidence interval) for neonatal mortality (antenatal steroid use versus non-use) ranged from 0.56 (0.46 to 0.67) at 22 to 25 weeks; 0.66 (0.53 to 0.83) at 26 to 28 weeks; 0.69 (0.55 to 0.85) at 29 to 33 weeks and 0.69 (0.47 to 1.01) at 34 to 36 weeks. Conclusion: These data are in accordance with meta-analytical data of randomized clinical trials and network reports on reduction of neonatal mortality with the use of antenatal steroids, and provide support for the use of antenatal steroids for late preterm births.

Original languageEnglish (US)
Pages (from-to)722-727
Number of pages6
JournalJournal of Perinatology
Volume32
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Steroids
Infant Mortality
Birth Certificates
Confounding Factors (Epidemiology)
Premature Birth
Gestational Age
Logistic Models
Death Certificates
Neonatal Intensive Care Units
Risk Reduction Behavior
Premature Infants
Meta-Analysis
Randomized Controlled Trials
Odds Ratio
Clinical Trials
Confidence Intervals

Keywords

  • antenatal steroids
  • neonatal mortality
  • reterm infants

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health

Cite this

Antenatal steroid use and neonatal outcome : United States 2007. / Malloy, Michael.

In: Journal of Perinatology, Vol. 32, No. 9, 09.2012, p. 722-727.

Research output: Contribution to journalArticle

@article{1e8a6bd81c764fbc932f76281b48ae54,
title = "Antenatal steroid use and neonatal outcome: United States 2007",
abstract = "Objective: Antenatal steroid use has been associated with reduction in the risk of neonatal mortality in meta-analyses of clinical trials. In 2007, a revised US birth certificate offered information on antenatal steroid use in 22 states. The aim of this study was to review the association between antenatal steroid use and neonatal mortality by gestational age categories for preterm infants (<37 weeks) for the United States for the year 2007. Study Design: Data were obtained from the United States Linked Infant Birth and Death Certificate Public Use Period file for the year 2007. Associations between antenatal steroid use and neonatal death were determined by logistic regression adjusting for potentially confounding variables. Result: There were 245 453 preterm births and 4220 neonatal deaths available for analysis with complete data on antenatal steroid use. The highest prevalence for antenatal steroid use among neonatal intensive care unit admissions (NICU) was 22{\%} in the 26 to 28 week gestational age category, whereas the lowest prevalence was in the 34-to 36-week group at 7{\%}. Following adjustment for potentially confounding variables by logistic regression, the adjusted odds ratios (95{\%} confidence interval) for neonatal mortality (antenatal steroid use versus non-use) ranged from 0.56 (0.46 to 0.67) at 22 to 25 weeks; 0.66 (0.53 to 0.83) at 26 to 28 weeks; 0.69 (0.55 to 0.85) at 29 to 33 weeks and 0.69 (0.47 to 1.01) at 34 to 36 weeks. Conclusion: These data are in accordance with meta-analytical data of randomized clinical trials and network reports on reduction of neonatal mortality with the use of antenatal steroids, and provide support for the use of antenatal steroids for late preterm births.",
keywords = "antenatal steroids, neonatal mortality, reterm infants",
author = "Michael Malloy",
year = "2012",
month = "9",
doi = "10.1038/jp.2012.22",
language = "English (US)",
volume = "32",
pages = "722--727",
journal = "Journal of Perinatology",
issn = "0743-8346",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Antenatal steroid use and neonatal outcome

T2 - United States 2007

AU - Malloy, Michael

PY - 2012/9

Y1 - 2012/9

N2 - Objective: Antenatal steroid use has been associated with reduction in the risk of neonatal mortality in meta-analyses of clinical trials. In 2007, a revised US birth certificate offered information on antenatal steroid use in 22 states. The aim of this study was to review the association between antenatal steroid use and neonatal mortality by gestational age categories for preterm infants (<37 weeks) for the United States for the year 2007. Study Design: Data were obtained from the United States Linked Infant Birth and Death Certificate Public Use Period file for the year 2007. Associations between antenatal steroid use and neonatal death were determined by logistic regression adjusting for potentially confounding variables. Result: There were 245 453 preterm births and 4220 neonatal deaths available for analysis with complete data on antenatal steroid use. The highest prevalence for antenatal steroid use among neonatal intensive care unit admissions (NICU) was 22% in the 26 to 28 week gestational age category, whereas the lowest prevalence was in the 34-to 36-week group at 7%. Following adjustment for potentially confounding variables by logistic regression, the adjusted odds ratios (95% confidence interval) for neonatal mortality (antenatal steroid use versus non-use) ranged from 0.56 (0.46 to 0.67) at 22 to 25 weeks; 0.66 (0.53 to 0.83) at 26 to 28 weeks; 0.69 (0.55 to 0.85) at 29 to 33 weeks and 0.69 (0.47 to 1.01) at 34 to 36 weeks. Conclusion: These data are in accordance with meta-analytical data of randomized clinical trials and network reports on reduction of neonatal mortality with the use of antenatal steroids, and provide support for the use of antenatal steroids for late preterm births.

AB - Objective: Antenatal steroid use has been associated with reduction in the risk of neonatal mortality in meta-analyses of clinical trials. In 2007, a revised US birth certificate offered information on antenatal steroid use in 22 states. The aim of this study was to review the association between antenatal steroid use and neonatal mortality by gestational age categories for preterm infants (<37 weeks) for the United States for the year 2007. Study Design: Data were obtained from the United States Linked Infant Birth and Death Certificate Public Use Period file for the year 2007. Associations between antenatal steroid use and neonatal death were determined by logistic regression adjusting for potentially confounding variables. Result: There were 245 453 preterm births and 4220 neonatal deaths available for analysis with complete data on antenatal steroid use. The highest prevalence for antenatal steroid use among neonatal intensive care unit admissions (NICU) was 22% in the 26 to 28 week gestational age category, whereas the lowest prevalence was in the 34-to 36-week group at 7%. Following adjustment for potentially confounding variables by logistic regression, the adjusted odds ratios (95% confidence interval) for neonatal mortality (antenatal steroid use versus non-use) ranged from 0.56 (0.46 to 0.67) at 22 to 25 weeks; 0.66 (0.53 to 0.83) at 26 to 28 weeks; 0.69 (0.55 to 0.85) at 29 to 33 weeks and 0.69 (0.47 to 1.01) at 34 to 36 weeks. Conclusion: These data are in accordance with meta-analytical data of randomized clinical trials and network reports on reduction of neonatal mortality with the use of antenatal steroids, and provide support for the use of antenatal steroids for late preterm births.

KW - antenatal steroids

KW - neonatal mortality

KW - reterm infants

UR - http://www.scopus.com/inward/record.url?scp=84865729593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865729593&partnerID=8YFLogxK

U2 - 10.1038/jp.2012.22

DO - 10.1038/jp.2012.22

M3 - Article

VL - 32

SP - 722

EP - 727

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 9

ER -